Aftercare for childhood cancer survivors in Switzerland
Aftercare of Childhood Cancer Survivors in Switzerland - the ACCS Switzerland Project
This study is trying to find out how childhood cancer survivors in Switzerland feel about their follow-up care as they transition from pediatric to adult healthcare, so they can improve support for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Kantonsspital Aarau Academic / other |
| Locations | 3 sites (Aarau and 2 other locations) |
| Trial ID | NCT04284189 on ClinicalTrials.gov |
What this trial studies
The Aftercare of Childhood Cancer Survivors in Switzerland (ACCS) study is a multicenter cohort investigation focused on the transition of follow-up care from pediatric oncology to adult care for adolescent and young adult survivors of childhood cancer. It aims to gather data on the preferences and expectations of these survivors regarding their follow-up care through questionnaires. The study addresses the critical need for effective transition strategies, as many survivors experience late effects from their treatment. By comparing different aftercare models, the study seeks to identify the best practices that meet the needs of these individuals.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 16 and older who are at least 5 years post-treatment for childhood cancer and currently in follow-up care.
Not a fit: Patients who have undergone surgery only without increased risk of late effects or those with severe cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the follow-up care and quality of life for childhood cancer survivors transitioning to adult care.
How similar studies have performed: While there have been studies on childhood cancer survivorship, this specific approach to comparing transition models is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 5-year survivor of childhood cancer * Diagnosis according to ICCC3 I-XII; Langerhans cell histiocytosis (LCH), Hemophagocytic lymphohistiocytosis (HLH) * Age at diagnosis \<18 years * Age at study ≥16 years * At study start in follow-up care at one of the three pediatric oncology centers (group before transition) or transitioned not before 2014 (group after transition). * Written informed consent Exclusion Criteria: * Treatment only by means of surgery and without increased risk of late effects (e.g. teratoma) * \<5 years after therapy of a relapse or palliative situation * Severe cognitive impairment, which makes it impossible to complete the questionnaire independently * Insufficient knowledge of the German language * Informed consent form not signed
Where this trial is running
Aarau and 2 other locations
- Division of Oncology - Hematology, Department of Pediatrics, Kantonsspital Aarau — Aarau, Switzerland (Recruiting)
- Division of Oncology/ Hematology, University Children's Hospital Basel — Basel, Switzerland (Recruiting)
- Division of Oncology/ Hematology, Department of Pediatrics, Kantonsspital Lucerne — Lucerne, Switzerland (Recruiting)
Study contacts
- Principal investigator: Katrin Scheinemann, MD — Kantonsspital Aarau
- Study coordinator: Katrin Scheinemann, MD
- Email: katrin.scheinemann@ksa.ch
- Phone: 004162 838 4909
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.